Risk Factors for Severe Infection and Mortality in COVID-19 and Monoclonal Gammopathy of Undetermined Significance

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19

Résumé en anglais

Vaccines have been 32 instrumental in reducing incidence and severity of COVID-19 with efficacy rate of about 95% reported in phase 3 clinical data for both the mRNA vaccines (Pfizer and Moderna). These studies excluded immunocompromised patients, including those with hematologic malignancies. Patients with multiple myeloma (MM) have inferior vaccine efficacy and COVID-19 infections are more severe, especially in patients being treated with anti-CD38 or anti-B-cell maturation antigen (BCMA) directed therapies5. Patients with monoclonal gammopathy of undetermined significance (MGUS) are at increased risk of infections from suboptimal immune responses and demonstrate higher risk of infections compared to age-matched controls. The data on clinical course of COVID-19 infections in patients with MGUS is limited and the impact of immune paresis on severity of infection needs additional evaluation.